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The aim of this study is to evaluate feasibility, acute and late 
toxicities and cosmetic results with a long follow-up. 
 
Material and Methods: Methods and materials: From January 
2005 to December 2013 a total of 445 patients were enrolled 
in the study, implanted during surgery and treated using a 
microSelectron-HDR brachytherapy Unit. The median age of 
the patients was 65 years (range 48-88 years). All those 
enrolled had an infiltrating ductal carcinoma in the absence 
of an extensive intraductal component and with clear surgical 
margins. Sentinel node biopsy was positive in 19,9% of 
patients and the 76,7% of patients have had estrogen 
therapy, 15,9% have had adjuvant chemotherapy. In the 
95.75 of patient the histology was ductal infiltranting 
carcinoma, in the 51% of cases the stage was T1b, in the 35% 
was T1c. Adjuvant chemotherapy was given to 15,9% of 
patients and hormone therapy to 76,7% of patients. The 
reference dose is taken as 85% of the mean basal dose. A 
reference dose of 35 Gy (3.5 Gy in two fractions per day) was 
delivered to 17% and a dose of 32 Gy (4 Gy in two fractions 
per day) to 83%. The average time of overall treatment was 
five days (76,8% in 4-5 days and 23,2% in 6-7 day); the 
difference is due to festivity and hospital provenience. 
Catheters were implanted (average of 14) guided by 
templates in most cases with distance between holes of 16 
mm, in a double or triple-plane arrangement in 99% of 
patients. The mean volume surrounded by the prescription-
isodose was 69,2 cc (range 13-129 cc). The treatment plans 
were evaluated in terms of skin dose, natural dose-
histogram, quality (mean 2,15 - range 1-3.04) and uniformity 
(mean 2.53 and range 1-3.54) index. 
 
Results: Results: The average overall treatment time is 
five/six days starting from implant commencement. The 
incidence of acute and late toxicities are given in Table I. 
Cosmetic results were excellent/good in 81% of patients. In a 
follow-up of 96 months we observed a local control of 7,7% 
and in 1,5% metastatic disease. 
Table II. Acute and late toxicities. 
 
 
Conclusion: Conclusions: The initial data demonstrates that 
an interstitial perioperative brachytherapy implant is a 
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Purpose or Objective: To assess the outcome of patients 
treated with CT guided HDR brachytherapy for cervical 
cancer 
 
Material and Methods: The records for 100 consecutive 
patients treated in our centre were reviewed. All patients 
prior to treatment had a biopsy for diagnosis, and a staging 
pelvic MRI and whole body PET scan. Treatment comprised of 
EBRT to a dose of 45Gy in 25 fractions given to the pelvis ± 
para-aortics with concurrent cisplatin chemotherapy. The 
brachytherapy was delivered in 3 fractions using a ring and 
tandem applicator with CT planning of each individual 
fraction and using information from a pre-implant planning 
MRI. The aim is to achieve HRCTV d90 of >80Gy whilst staying 
within the published parameters for the OARs. The outcomes 
in terms of survival and pattern of relapse were recorded and 
correlated with the HRCTV d90 and volume, and the dose to 
the OARs. The unpaired t-test and pearson correlation 
coefficient were used with 2-tailed significance testing level 
of 0.05. 
 
Results: The median follow up was 32 months with a median 
age at time of treatment of 44 years (21 – 85 years). Most 
patients were diagnosed with squamous cell carcinoma (77) 
or adenocarcinoma (17), 3 patients had an adenosquamous 
carcinoma and there were 4 cases with unusual histological 
findings of small cell, serous papillary (2) or neuroendocrine 
carcinomas. At the time of follow up 78 patients are alive, 21 
died from disease and 1 died from unrelated causes. The 
median time to relapse was 8 months (range 1-23 months). 
There were 2 cases of isolated pelvic central recurrences, 11 
cases of pelvic and distant metastases and 8 cases with only 
distant disease. The median d90 was 83.9Gy and the mean 
HRCTV volume was 32.3cm3 (range 9.0 – 83.9cm3). There was 
a statistically significant difference in d90 between patients 
with relapse v.s. no relapse (t= 2.49, p=0.019) and there was 
a strong negative correlation between the HRCTV volume and 
the d90 (r= -0.48, p<0.0001). The median doses to the OARs: 
rectum 60.3Gy (46.8 – 74.1Gy), sigmoid 66.9Gy (46 – 76.5Gy), 
small bowel 59.1Gy (43.7 – 75Gy) and bladder 75Gy (51.4 – 
93.9Gy). There were 3 cases with grade 3-4 toxicity that 
could be related to the brachytherapy: 1 vesico-vaginal 
fistula, 1 recto-vaginal fistula, and 1 post treatment 
hydronephrosis. 
 
Conclusion: CT guided cervical brachytherapy allows the 
delivery of adequate radiation doses to the HRCTV as shown 
by our acceptable local control and toxicity rates. The 
pattern of distant disease in the majority of relapses 
indicates that despite optimal staging investigations and 
adequate radiation doses to the HRCTV, distant undetected 
microscopic disease will still determine the outcome in a 
proportion of cases. 
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Purpose or Objective: Image guided plan optimisation with 
MRI and CT for interstitial and intracavitary brachytherapy is 
an established technique in treating cervical cancer. The 
purpose of this current study is to assess the feasibility of 
boosting the dose to GTV(BT) to 140% of the HRCTV 
prescription dose, while keeping critical structure dose 
volume histograms within tolerance. 
 
Material and Methods: 14 MRI/CT guided treatment plans 
were analysed in this study. Patients were treated using 
either Vienna-style ring applicator or Fletcher-style 
applicator, with or without interstitial catheters. The median 
age of the patients was 51.5 years (range 25-80.2 years). One 
patient had FIGO Stage IB cancer, 10 had stage IIB cancer and 
3 had stage IIIB cancer. All received IMRT external beam 
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radiotherapy (50.2Gy/27#, 50Gy/25# or 45Gy/25#) followed 
by brachytherapy (26Gy/4# or 28Gy/4# to HRCTV). In the 
current study the original treatment plans were re-optimised, 
using Brachyvision Version 11. The aim was to escalate the 
GTV(BT) dose to 140% of the original HRCTV prescription dose 
(8.4Gy and 9.8Gy/# respectively), keeping the HRCTV 
coverage and organ at risk DVH values within the tolerance 
which had been accepted for the original clinical plans. GTV 
(BT) and HRCTV were drawn according to GEC-ESTRO 
recommendations. The relationship between the volumes can 
be defined by the following equation. HRCTV2 = HRCTV1 – 
GTV(BT) The quality of the re-optimised plans was quantified 
by using dose volume histogram parameters. 
 
Results: Table 1 shows a comparison of the original and the 
re-optimised plan parameters.In 10 out of the 14 cases 
(71.4%) more than 90% of the GTV(BT) was covered by the 
140% isodose after re-optimisation.The HRCTV1 V100% was 
reduced for the re-optimised plans by an average of 2.95% 
(range 0.7-6.01%).Average coverage of HRCTV2 with the 
prescription isodose was 94.5% for the 6Gy plans, and 81.7% 
for the 7Gy plans.In 12 out of the 14 cases (85.7%) the 
treatment time was reduced with the boost plan.  
 
Conclusion: It is possible to boost the prescription dose to 
the GTV(BT) to 140% for treatment plans with interstitial 
catheters and IU within the GTV(BT) volume. Plans without 
both interstitial catheters and IU in the GTV(BT) are most 
likely to be suboptimal. This planning study demonstrates 
that dose escalation to the GTV(BT) is feasible if clinically 
indicated, and further work into clinical application and 
outcome should be considered. 
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Purpose or Objective: Locally advanced cervical cancer 
patients with a bulky high-risk clinical target volume (HR-
CTV) get the largest benefit of dose escalation in terms of 
local control. But the expected survival benefit could be 
lessened by a higher metastatic risk. We examined the 
patterns of relapse according to the HR-CTV and to the 
ability to reach the target dose. 
 
Material and Methods: Pts treated with chemoradiation 
between 04/2007 and 02/2012 were included if they had a 
disease limited to the pelvis after an exhaustive primary 
staging (PET/CT plus primary laparoscopic para-aortic 
lymphadenectomy) and if they had received concurrent 
chemotherapy. Pts received pelvic irradiation (45 Gy) then a 
PDR brachytherapy boost +/- a pelvic sequential boost for 
PET positive pelvic lymph nodes. First sites of relapse were 
examined. 
 
Results: 109 pts were included, with median follow-up of 39 
months. Median D90 HR-CTV was 73.5 Gy in case of HR-CTV ≥ 
30 cm3 (n = 28) versus 86.4 Gy in case of HR-CTV < 30 cm3 (p 
< 0.001). Pts with a not-bulky HR-CTV (< 30 cm3) experienced 
local failure in 5/81 (6.2%), versus in 6/28 (21.4 %) in case of 
bulky HR-CTV (p =0.03), but the HR-CTV volume did not 
correlate with the risk of local failures as only events. Pts 
with a bulky HR-CTV volume had a higher risk of distant 
failures: 10/28 (35.8 %) versus 7/81 (8.6 %) in case of not-
bulky HR-CTV (p = 0.002). Local failures were seen in 3/47 
(6.4 %) for pts with a D90 HR-CTV ≥ 85 Gy and in 8/62 (12.9 
%) for pts with a D90 HR-CTV < 85 Gy, respectively (p=0.055). 
Distant failures were seen in 1/47 (2.1 %) and in 16/62 (25.8 
%), respectively (p<0.001). This higher frequency of distant 
events in pts with a D90 HR-CTV < 85 Gy remained significant 
after exclusion of local failures: 0/44 (0 %) versus 11/54 (20.4 
%), respectively (p < 0.001). 
 
Conclusion: The inability to reach the target dose seems 
correlated with a higher propensity to metastases. Strategies 
integrating the metastatic risk are mandatory for maximizing 
the benefit of dose escalation. 
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Purpose or Objective: GEC-ESTRO recommendations for IGRT 
in brachytherapy, the incorporation of MRI in the planning 
and new MRI-compatible applicators have improved our 
treatments. But, in big tumours, intrauterine applicators 
don´t seem enough in order to reach a good coverage. 
Interstitial CT-MRI Utrecht (Elekta®) applicator with plastic 
needles lets improve HR-CTV and IR-CTV coverage sparing 
organs at risk. However, a further complication using 
interstitial applicators may be gynaecological bleeding during 
the withdrawal of the applicator.  
The purpose of this study is to review perioperative toxicity 
and dosimetry in patients with cervix tumours using 
interstitial CT-MRI Utrecht applicator. 
 
Material and Methods: Retrospective review of the records 
of 122 cervical cancer patients treated in our institution from 
